ArticleJournal of medical biochemistry2026
Role of coagulation irregularities in cholangiocarcinoma: A review.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Narrative Review on Abnormalities in the Hemostatic System in Diabetes Mellitus: Pathophysiology, Clinical Implications, and Therapeutics.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) is a malignancy that originates from the biliary epithelium, presenting either intrahepatically or extrahepatically. A late-stage diagnosis and a poor overall prognosis characterise it. D-dimer, a biomarker indicative of coagulation and fibrinolysis activation, is believed to play a significant role in cancer progression, with elevated plasma levels correlating positively with metastatic disease and advanced cancer stages. In intrahepatic CCA, fibrinogen has been identified as an independent prognostic factor associated with adverse outcomes and reflects systemic inflammatory responses. The increased expression of urokinase-type plasminogen activator has been linked to lymphatic invasion and metastatic spread in CCA patients. Additionally, a preoperative elevation in prothrombin time may predict reduced survival rates for individuals undergoing potentially curative surgical interventions. P-selectin, which interacts predominantly with leukocyte ligands, has the potential to promote tumourigenesis and facilitate metastatic dissemination of mucin-producing carcinomas. Moreover, prolonged activated partial thromboplastin time may provide valuable insights into the extent of parenchymal involvement in CCA. This review aims to elucidate the role of coagulation abnormalities within the pathophysiology of cholangiocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.